{Reference Type}: Journal Article
{Title}: Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.
{Author}: Santos-García D;de Deus T;Cores C;Feal Painceiras MJ;Íñiguez Alvarado MC;Samaniego LB;López Maside A;Jesús S;Cosgaya M;García Caldentey J;Caballol N;Legarda I;Hernández-Vara J;Cabo López I;López Manzanares L;González-Aramburu I;Ávila A;Gómez-Mayordomo V;Nogueira V;Dotor García-Soto J;Borrué-Fernández C;Solano B;Álvarez Sauco M;Vela L;Escalante S;Cubo E;Mendoza Z;Pareés I;Sánchez Alonso P;Alonso Losada MG;López-Ariztegui N;Gastón I;Kulisevsky J;Seijo M;Valero C;Alonso Redondo R;Buongiorno MT;Ordás C;Menéndez-González M;McAfee D;Martinez-Martin P;Mir P; ;
{Journal}: Mov Disord Clin Pract
{Volume}: 11
{Issue}: 7
{Year}: 2024 Jul 15
{Factor}: 4.514
{DOI}: 10.1002/mdc3.14056
{Abstract}: <B>BACKGROUND: </B>Levodopa-induced dyskinesias (LID) are frequent in Parkinson's disease (PD).<BR><B>OBJECTIVE: </B>To analyze the change in the frequency of LID over time, identify LID related factors, and characterize how LID impact on patients' quality of life (QoL).<BR><B>METHODS: </B>PD patients from the 5-year follow-up COPPADIS cohort were included. LID were defined as a non-zero score in the item "Time spent with dyskinesia" of the Unified Parkinson's Disease Rating Scale-part IV (UPDRS-IV). The UPDRS-IV was applied at baseline (V0) and annually for 5 years. The 39-item Parkinson's disease Questionnaire Summary Index (PQ-39SI) was used to asses QoL.<BR><B>RESULTS: </B>The frequency of LID at V0 in 672 PD patients (62.4 ± 8.9 years old; 60.1% males) with a mean disease duration of 5.5 ± 4.3 years was 18.9% (127/672) and increased progressively to 42.6% (185/434) at 5-year follow-up (V5). The frequency of disabling LID, painful LID, and morning dystonia increased from 6.9%, 3.3%, and 10.6% at V0 to 17.3%, 5.5%, and 24% at V5, respectively. Significant independent factors associated with LID (P < 0.05) were a longer disease duration and time under levodopa treatment, a higher dose of levodopa, a lower weight and dose of dopamine agonist, pain severity and the presence of motor fluctuations. LID at V0 (β = 0.073; P = 0.027; R2 = 0.62) and to develop disabling LID at V5 (β = 0.088; P = 0.009; R2 = 0.73) were independently associated with a higher score on the PDQ-39SI.<BR><B>CONCLUSIONS: </B>LID are frequent in PD patients. A higher dose of levodopa and lower weight were factors associated to LID. LID significantly impact QoL.